-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26

Benzinga·10/31/2025 10:50:44
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $20 to $26.